Register and share your invite link to earn from video plays and referrals.

Search results for AFA2026
AFA2026 community
One keyword maps to one global community path.
Create community
People
Not Found
Tweets including AFA2026
#AFASG26# SINGAPORE, ARE YOU READY? 🔥 3 days. 38 performers. 200+ exhibitors. ONE EPIC AFA. 200+ exhibitors, 160+ cosplay & creators, 25+ special guests, 36+ showcases, 38 concert performers — see you 27–29 Nov! 🎟️ #AnimeFestivalAsia# #AFA2026#
Show more
With #ADA2026# right around the corner, now’s the perfect time to familiarize yourself with the latest in ketone monitoring with our free, CME-accredited masterclass series; designed to enhance your confidence and decision-making:
Show more
The conversations at #ADA2026# are helping to build a new era of care.
That’s a wrap on #ADA2026#. It left us with important reminders about why science matters and who it’s for. #WeAreLilly#
NEW Phase 3 data today at #ADA2026#: Lilly's investigational triple agonist met all primary endpoints in TRIUMPH-1. Patients on the 12 mg dose lost an avg of 70 pounds (28.3%) over 80 weeks. Read more:
Show more
New data: Our oral GLP-1 delivered superior A1C control and weight loss across three clinical trials. Read more: #ADA2026#
Women at every stage of menopause — pre, peri and post — experienced meaningful weight loss in post-hoc analyses of two studies of one of our obesity medicines presented at #ADA2026#. Up to 30 pounds lost on the highest dose at 72 weeks. Read more:
Show more
Adults with type 2 diabetes on our investigational triple agonist saw significant A1C reductions at 40 weeks in the TRANSCEND-T2D-1 trial. Results presented today at #ADA2026# and published simultaneously in @TheLancet. Read more:
Show more
In addition to weight loss, our investigational triple agonist reduced moderate-to-severe obstructive sleep apnea severity by an average 61 percent on the 9 mg dose in the TRIUMPH-1 study. Presented today at #ADA2026#. Read more:
Show more